Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Rheumatologists share how they are using AI platforms for clinical documentation, reducing EHR time, streamlining workflows, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果